LEVEMIR FLEXTOUCH (insulin detemir) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2005.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
LEVEMIR FLEXTOUCH (insulin detemir) is a long-acting basal insulin analog administered subcutaneously via pre-filled FlexTouch pen device. It is indicated for the treatment of diabetes mellitus to improve glycemic control in patients requiring insulin therapy. The drug works as an insulin analog that binds to the insulin receptor, facilitating glucose uptake and metabolism. It represents a mature, well-established therapy in the basal insulin class and serves as a foundational component of insulin regimens for both type 1 and type 2 diabetes management.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Worked on LEVEMIR FLEXTOUCH at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$184M Medicare spend — this is a commercially significant brand
This mature product creates roles primarily in brand management, market access, field sales, and managed care positions focused on defending market share against generic erosion and competing basal insulin products. Key skills include payer negotiation, formulary strategy, and competitive intelligence in the commoditized insulin market. Currently, there are zero open positions linked to this product in the job market, reflecting its mature, stable status with minimal active hiring initiatives.